The yin and yang of ERBB4: tumor suppressor and oncoprotein

LM Lucas, V Dwivedi, JI Senfeld, RL Cullum… - Pharmacological …, 2022 - ASPET
ERBB4 (HER4) is a member of the ERBB family of receptor tyrosine kinases, a family that
includes the epidermal growth factor receptor (EGFR/ERBB1/HER1), ERBB2 (Neu/HER2) …

The role of ErbB4 in cance r

VFM Segers, L Dugaucquier, E Feyen, H Shakeri… - Cellular oncology, 2020 - Springer
Background The epidermal growth factor receptor family consists of four members, ErbB1
(epidermal growth factor receptor-1), ErbB2, ErbB3, and ErbB4, which all have been found …

[HTML][HTML] Chemotherapy-induced apoptosis, autophagy and cell cycle arrest are key drivers of synergy in chemo-immunotherapy of epithelial ovarian cancer

J Wahba, M Natoli, LM Whilding… - Cancer Immunology …, 2018 - Springer
Epithelial ovarian cancer (EOC) is the most lethal of all gynecological malignancies in the
UK. Recent evidence has shown that there is potential for immunotherapies to be successful …

Synergistic chemoimmunotherapy of epithelial ovarian cancer using ErbB-retargeted T cells combined with carboplatin

AC Parente-Pereira, LM Whilding, N Brewig… - The Journal of …, 2013 - journals.aai.org
Epithelial ovarian cancer (EOC) remains the most lethal gynecologic malignancy,
underscoring the need for better therapies. Adoptive immunotherapy using genetically …

Genome-wide analysis of common copy number variation and epithelial ovarian cancer risk

BM Reid, JB Permuth, YA Chen, BL Fridley… - … , biomarkers & prevention, 2019 - AACR
Background: Germline DNA copy number variation (CNV) is a ubiquitous source of genetic
variation and remains largely unexplored in association with epithelial ovarian cancer (EOC) …

Advanced development of ErbB family-targeted therapies in osteosarcoma treatment

W Wang, H Zhao, T Yao, H Gong - Investigational new drugs, 2019 - Springer
Osteosarcoma (OS) is the most common primary aggressive and malignant bone tumor.
Newly diagnostic OS patients benefit from the standard therapy including surgical resection …

[HTML][HTML] ErbB4 promotes malignant peripheral nerve sheath tumor pathogenesis via Ras-independent mechanisms

JF Longo, SN Brosius, L Black, SH Worley… - Cell Communication and …, 2019 - Springer
Background We have found that erbB receptor tyrosine kinases drive Ras hyperactivation
and growth in NF1-null malignant peripheral nerve sheath tumors (MPNSTs). However …

[HTML][HTML] Overexpression of ERBB4 JM-a CYT-1 and CYT-2 isoforms in transgenic mice reveals isoform-specific roles in mammary gland development and …

VB Wali, M Gilmore-Hebert, R Mamillapalli… - Breast Cancer …, 2014 - Springer
Abstract Introduction Human Epidermal Growth Factor Receptor (ERBB4/HER4) belongs to
the Epidermal Growth Factor receptor/ERBB family of receptor tyrosine kinases. While …

Targeting HER (ERBB) signaling in head and neck cancer: An essential update

J Zhang, NF Saba, GZ Chen, DM Shin - Molecular aspects of medicine, 2015 - Elsevier
HNC (head and neck cancer) remains the 6th most common carcinoma worldwide. The
suboptimal survival and toxicities observed with conventional approaches warrant …

[HTML][HTML] Directing HER4 mRNA expression towards the CYT2 isoform by antisense oligonucleotide decreases growth of breast cancer cells in vitro and in vivo

TO Nielsen, S Sorensen, F Dagnæs-Hansen… - British journal of …, 2013 - nature.com
Background: The tyrosine kinase receptor HER4 is a member of the epidermal growth factor
receptor (EGFR) family. It plays diverse roles in cancer development and cancer progression …